MoST-LLy Study

The Molecular Screening and Therapeutics (MoST) Program is a clinical research program that is testing a new approach to providing treatments for patients with cancer. MoST-LLy is a cohort within MoST that is just for patients with blood cancers. The MoST program personalises experimental treatment based on an individual’s unique cancer genetic profile, rather than where their cancer originates.

If a patient is suitable for the program, their blood cancer is tested to see if the DNA contains genetic biomarkers that can guide treatment. This process is called molecular screening or genetic testing. After a patient’s blood cancer is tested, a report is sent to their referring haematologist with information on (i) any genetic biomarkers that were identified and (ii) the types of treatment that may be suitable.

QIMR Berghofer is now a national remote consenting hub for the MoST-LLy study extending access for patients to all parts of Australia.

For further information about this program see also Understanding the Blood Cancer Genomics Trial: Leukaemia Foundation (Australia).

The MoST-LLy research program is a collaboration between QIMR Berghofer, led by Professor Steven Lane, Group leader of The Gordon and Jessie Gilmour Leukaemia Research Laboratory at QIMR Berghofer and clinical haematologist at Royal Brisbane and Women’s Hospital, the Garvan Institute of Medical Research, SA Pathology, PathWest, Omico (the Australian Genomic Cancer Medicine Centre) and the NHMRC Clinical Trials Centre at the University of Sydney. This program has ethics approval from St Vincent’s Hospital Human Research Ethics Committee (2019/ETH03114) and the University of Sydney is the regulatory sponsor of clinical trials undertaken through the program. MoST-LLy has generously been co-funded by The Leukemia Foundation, Tour de Cure and the Medical Research Future Fund (MRFF).

Further information can be found following external links:

• LFA Blood Cancer Genomics Trial
• Omico

Chief Investigator: Prof Steven Lane (Clinical Lead)

Clinical Trials Project Managers: Gerlinda Amor and Helen Christensen

Contact details for queries:

• Phone: (07) 3845 3766 or 0487 400 607

• Email: mostlly@qimrb.edu.au

What is the MoST-LLy Study?

The fundamental premise of the MoST-LLy study is that innovations in genetic screening of blood cancers are needed to expedite translation of discovery into improved health outcomes for patients. The MoST-LLy study is testing a new approach to genetic screening of patients with blood cancer and reviewing eligibility for new treatments where possible.

Process:

1. Referral from Haematologist

2. Extraction of blood cancer DNA

3. Genetic sequencing and analysis

4. Discuss results with Haematologist

5. Follow up to review any treatment referrals

If a patient is suitable for the MoST-LLy study, and consents to participate, their blood cancer is tested to see if their DNA contains genetic biomarkers that may guide treatment. This process is called molecular screening or comprehensive genetic panel (CPG) testing. After a patient’s blood cancer is tested, a report is sent to the referring haematologist including:

(i) Any genetic biomarkers that were identified in the blood cancer, and

(ii) Any types of treatment that may be suitable (if found).

Who is suitable for the MoST-LLy Program?

Blood cancer patients 18 years and over, with advanced blood cancer of any type.

How can a patient enrol in the MoST-LLy Program?

A patient is asked to discuss the MoST-LLy study with their treating Haematologist.

Haematologist’s can review eligibility criteria and refer potentially eligible patient’s through a secure online MoST-LLy referral form with the patients medical history and a Pathology Report (to confirm the type of blood cancer and assist the study team to request a sample for testing).

If you are interested in the MoST-LLy study and would like a copy of the eligibility criteria or the MoST-LLy Referral form, please contact the Clinical Trial Project Managers, listed below.

The ethical aspects of this study have been approved by the HREC of Metro South Health EC00167 (HREC/2024/QMS/113451).

This study is made possible through the support of the Leukaemia Foundation of Australia, Tour de Cure and an MRFF Grant with CIA Prof Steven Lane.

• patients with advanced blood cancer of any type
• patients aged 18 years and over